Cedar Mountain Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Cedar Mountain Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-5	Closed	-$157	–	1180
2026 Q2	$157	Hold	5	–	–	﹤0.01%	1141
2026 Q1	$124	Buy	+5	New	+$119	﹤0.01%	1114

Other funds holding CPRX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Cedar Mountain Advisors's CPRX Position: Q3 2026 in Review

Cedar Mountain Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 5 shares — an estimated $157 sold.

Cedar Mountain Advisors first reported a position in CPRX in Q1 2026 and held it in 2 quarters. The position peaked at $157 in Q2 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.

Cedar Mountain Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Cedar Mountain Advisors sold 5 Catalyst Pharmaceutical shares in Q3 2026, an estimated $157.
Cedar Mountain Advisors first reported a position in Catalyst Pharmaceutical in Q1 2026 and held it in 2 quarters.
Cedar Mountain Advisors's Catalyst Pharmaceutical position peaked at $157 in Q2 2026.
1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.